v3.25.2
Acquisitions and License Agreements (Additional Information) (Details)
$ / shares in Units, ₩ in Billions
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 17, 2025
USD ($)
$ / shares
shares
Feb. 22, 2025
USD ($)
Jun. 14, 2022
USD ($)
shares
May 31, 2022
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
shares
Jun. 30, 2025
KRW (₩)
shares
Feb. 28, 2025
Aug. 30, 2024
$ / shares
shares
Jun. 18, 2024
shares
Business Acquisition [Line Items]                          
Common stock, par value | $ / shares         $ 0.0001   $ 0.0001   $ 0.0001        
Payment to acquire license             $ 1,000,000            
Common stock, shares issued | shares         6,955,694   6,955,694   6,951,622 6,955,694     3,250,000
Ownership Interest Rate 60.00%                        
Royalty expenses         $ 100,000 $ 100,000 $ 100,000 $ 100,000          
Accrued Royalty Payables             100,000   $ 100,000        
Additional paid-in capital         453,049,000   453,049,000   454,614,000        
Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]                          
Business Acquisition [Line Items]                          
Common stock, par value | $ / shares                       $ 0.0001  
Common stock, shares issued | shares                       8,571  
VIE [Member]                          
Business Acquisition [Line Items]                          
Ownership Equity Interest Rate 60.00%                        
Tlido Rest Of World License Agreement [Member]                          
Business Acquisition [Line Items]                          
Percentage of Lidocaine Topical System   1.80%                      
Aggregate Payment Of Company   $ 200,000                      
Gloperba Rest of World License Agreement [Member]                          
Business Acquisition [Line Items]                          
Revenue, Remaining Performance Obligation, Percentage                     50.00%    
Elyxyb Rest of World License Agreement [Member]                          
Business Acquisition [Line Items]                          
Revenue, Remaining Performance Obligation, Percentage                     50.00%    
Patents [Member] | Sorrento [Member]                          
Business Acquisition [Line Items]                          
Payment upon the achievement of net sales       $ 20,000,000                  
Amount due for New Drug Application       $ 3,000,000                  
Scilex Pharma [Member] | Tlido Rest Of World License Agreement [Member]                          
Business Acquisition [Line Items]                          
Revenue, Remaining Performance Obligation, Percentage   50.00%                      
Scilex Bio JV [Member]                          
Business Acquisition [Line Items]                          
Common stock, shares issued | shares 5,000,000                        
Ownership Interest Rate 40.00%                        
Historical carrying value of semnur shares $ 0                        
Percentage of estimated fair value expensed as in-process research and development 40.00%                        
Estimated fair value expensed as in-process research and development net $ 8,100,000                        
In process research and development amount of estimated fair value 4,400,000                        
Initial upfront payment due under the licensing arrangement recognised as current liability 1,100,000                        
Additional paid-in capital 1,500,000                        
Net income for Scilex Bio attributable to the noncontrolling interest $ 1,700,000                        
Aggregate amount payable under license agreements         4,800,000,000   4,800,000,000     ₩ 6,500.0      
Upfront fee payable under license agreement         1,100,000   1,100,000     1.5      
Upfront fee payable under license agreement contingent upon the achievement of specified development, regulatory, and commercial milestone         $ 50,700,000   $ 50,700,000     ₩ 68.5      
Percentage of royalties on sales payable until expiration of licensed patent         5.00%   5.00%     5.00%      
Aggregate amount payable under license agreements capped amount         $ 4,800,000,000   $ 4,800,000,000     ₩ 6,500.0      
Upfront fee payable first tranche.         1,100,000   1,100,000     ₩ 1.5      
Scilex Bio JV [Member] | Semnur Merger Agreement And Sponsor Interest Purchase Agreement [Member]                          
Business Acquisition [Line Items]                          
Common stock, par value | $ / shares $ 0.00001                        
License Agreement                          
Business Acquisition [Line Items]                          
Development milestones payment was recognized under other long-term liabilities         200,000   200,000   200,000        
License Agreement | Romeg License Agreement [Member]                          
Business Acquisition [Line Items]                          
Up-front license fee     $ 2,000,000                    
Payment upon the achievement of net sales     13,000,000                    
Payments for royalties     150,000                    
Intangible asset     5,700,000                    
Deferred consideration     3,700,000                    
Contingent consideration, liability         0   0   $ 0        
Non-Refundable, Non-Creditable Payment     $ 700,000                    
Transfer of Common Stock Shares | shares     22,267                    
Royalty expenses         $ 300,000 $ 300,000 $ 300,000 $ 300,000